Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | CRHBP | P24387 | 1/20 | 0.73 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | NOD2 | Q9HC29 | 6/20 | 0.65 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | F10 | P00742 | 2/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489155 | 1.00 | KDM4E (0.73) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL6752352 | 0.88 | KDM4E (0.71) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL4215637 | 0.86 | KDM4E (0.70) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL13742183 | 0.86 | KDM4E (0.70) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL3259707 | 0.86 | NOD2 (0.71) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL8686408 | 0.85 | SMN1; SMN2 (0.68) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL15622712 | 0.85 | KDM4E (0.68) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL15622413 | 0.85 | KDM4E (0.68) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL28669136 | 0.85 | NOD2 (0.70) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 | |
| SCHEMBL8478235 | 0.84 | KDM4E (0.78) | KDM4ECRHBPCRHR2SMN1; SMN2NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-107787322-B | Tricyclic compounds and their use as phosphodiesterase inhibitors | 辉瑞大药厂 | 2023-07-07 | — | — | CN | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PFIZER, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3766885-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3766885-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3766885-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3310784-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS. | PFIZER (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3310784-B1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS. | PFIZER (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PFIZER INC. (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3310784-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | Pfizer Inc (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203347-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203347-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PFIZER INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12049465-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
| US-20230146535-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
| US-11472805-B2 | Tricyclic compounds and their use as phosphodiesterase inhibitors | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
| US-20190263816-A1 | Tricyclic Compounds And Their Use As Phosphodiesterase Inhibitors | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
| US-20230002386-A1 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE5A | KDM4E 1433/4885CRHBP 3448/4885CRHR2 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.